CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5950
-0.1050 (-3.89%)
As of 11:52AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.7000
Open2.7100
Bid2.620 x 1800
Ask2.620 x 900
Day's Range2.5700 - 2.7200
52 Week Range2.0800 - 5.9400
Volume75,013
Avg. Volume272,349
Market Cap131.629M
Beta (3Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-1.545
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
Trade prices are not sourced from all markets
  • What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
    Zacks4 days ago

    What Lies Ahead for Abbott (ABT) Stock This Earnings Season?

    Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.

  • 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
    Zacks5 days ago

    4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

    Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.

  • GlobeNewswire18 days ago

    Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 10:00 a.m. PT (1:00 p.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA. Dr. Berrey will present a corporate overview with plans and expected milestones for 2019, which will highlight the Company's core focus on progressing both oral, short-course brincidofovir (BCV) and the intravenous (IV) BCV program. Following planned discussions with FDA, the Company intends to progress IV BCV into a proof-of-concept study for the treatment of BK virus in kidney transplant recipients, while completing the phase 2 studies initiated during 2018 of IV BCV in adult stem cell transplant recipients with adenovirus infection.

  • Should You Avoid Chimerix Inc (CMRX)?
    Insider Monkeylast month

    Should You Avoid Chimerix Inc (CMRX)?

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]

  • 5 Beaten-Down Medical Product Stocks to Rebound in 2019
    Zackslast month

    5 Beaten-Down Medical Product Stocks to Rebound in 2019

    As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

  • Simply Wall St.last month

    Is Chimerix, Inc. (NASDAQ:CMRX) Overpaying Its CEO?

    M. Berrey became the CEO of Chimerix, Inc. (NASDAQ:CMRX) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...

  • Associated Press2 months ago

    Chimerix: 3Q Earnings Snapshot

    The Durham, North Carolina-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Chimerix Announces Third Quarter 2018 Financial Results

    - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Nov. 08, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address.

  • GlobeNewswire2 months ago

    Chimerix to Present at the Stifel 2018 Healthcare Conference

    DURHAM, N.C., Nov. 07, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today.

  • The most valuable public companies in the Triangle (Slideshow)
    American City Business Journals3 months ago

    The most valuable public companies in the Triangle (Slideshow)

    The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.

  • GlobeNewswire3 months ago

    Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018

    DURHAM, N.C., Nov. 01, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced.

  • GlobeNewswire3 months ago

    Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018

    Chimerix (CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV) against polyomavirus. Polyomaviruses are a family of small DNA viruses that persistently infect their hosts for life.

  • Simply Wall St.3 months ago

    How Should You Think About Chimerix Inc’s (NASDAQ:CMRX) Risks?

    If you’re interested in Chimerix Inc (NASDAQ:CMRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...

  • Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks5 months ago

    Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates

    Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?